Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project

de Witte, TM; Suciu, S; Anak, O; Hagemeijer-Hausman, Anne; Selleslag, D; Ferrant, A; Delforge, Michel; Belhabi, A; Schouten, H; Gratwohl, A; Aul, C; Aivado, M; Amadori, S; Muus, P; Tigaud, I; Jotterand-Bellomo, M; Willemze, R

Blood

Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project

Author:

de Witte, TM

Suciu, S ; Anak, O ; Hagemeijer-Hausman, Anne ; Selleslag, D ; Ferrant, A ; Delforge, Michel ; Belhabi, A ; Schouten, H ; Gratwohl, A ; Aul, C ; Aivado, M ; Amadori, S ; Muus, P ; Tigaud, I ; Jotterand-Bellomo, M ; Willemze, R

Keywords:

Science & Technology, Life Sciences & Biomedicine, Hematology, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine, Immunology, 3101 Biochemistry and cell biology, 3201 Cardiovascular medicine and haematology, 3213 Paediatrics

Blood Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project

Author:

Keywords:

Blood

Intensive chemotherapy versus autologous or allogeneic stemcell transplantation for the treatment of patients with poor risk MDS and secondary AML-A joint study of the Eortc, Ebmt, Hovon, Swiss, Scandinavian and Gimema leukemia groups: A biomed-2 EU-project